

# Molecular Modeling of Allosteric Site of Isoform-Specific Inhibition of the Peroxisome Proliferator-activated Receptor PPAR $\gamma$

*Suliman Almahmoud<sup>1\*</sup> and Haizhen A. Zhong<sup>2\*</sup>*

<sup>1</sup> Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraidah 51452, Saudi Arabia

<sup>2</sup> Department of Chemistry, University of Nebraska at Omaha, Omaha, Nebraska 68182, United States

\* Correspondence: HAZ: hzhong@unomaha.edu; Tel.: (1) (402) 554-3145; co-Correspondence: SA; s.a.almahmoud@hotmail.com.

Table S1. The chemical structures of PPAR $\gamma$  antagonists.

Table S2. The chemical structures of PPAR $\gamma$  antagonists.


Figure S1. The chemical structures of PPAR $\gamma$  agonists.

Table S3. Glide docking scores (GScore, kcal/mol) of drug-like molecules extracted from a NCI database Against the PPAR $\gamma$  (2HFP) at allosteric site.

Table S4. Interacting residues of PPAR $\gamma$  antagonists at the orthosteric site.


Table S5. Interacting residues of PPAR $\gamma$  agonists at the orthosteric site and the allosteric site based on the Induced-Fit Docking.

**Table S1.** The chemical structures of PPAR $\gamma$  antagonists taken from Hopkins' paper [1].






Compound	R	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>
<b>NSI</b>	H	4-CH <sub>3</sub> OPh	Ph	3-CF <sub>3</sub> Bn
<b>1</b>	H	4-CH <sub>3</sub> OPh	4-F-Ph	3-CF <sub>3</sub> Bn
<b>2</b>	H	4-CH <sub>3</sub> OPh	2-CO <sub>2</sub> MePh	3-CF <sub>3</sub> Bn
<b>3</b>	H	4-CH <sub>3</sub> OPh	2-CH <sub>3</sub> Ph	3-CF <sub>3</sub> Bn
<b>4</b>	H	4-CH <sub>3</sub> OPh	Me	3-CF <sub>3</sub> Bn
<b>5</b>	H	H	Ph	3-CF <sub>3</sub> Bn
<b>6</b>	H	H	4-F-Ph	3-CF <sub>3</sub> Bn
<b>7</b>	H	H	4-Cl-Ph	3-CF <sub>3</sub> Bn
<b>8</b>	H	H	3-CF <sub>3</sub> -Ph	3-CF <sub>3</sub> Bn
<b>9</b>	H	H	4-CH <sub>3</sub> Ph	3-CF <sub>3</sub> Bn
<b>10</b>	H	H	2-CH <sub>3</sub> Ph	3-CF <sub>3</sub> Bn
<b>11</b>	H	H	2-Naphthyl	3-CF <sub>3</sub> Bn
<b>12</b>	H	H	2-CF <sub>3</sub> -Ph	3-CF <sub>3</sub> Bn
<b>13</b>	H	H	2-(5-Chlorothiophene)	3-CF <sub>3</sub> Bn
<b>14</b>	H	H	Me	3-CF <sub>3</sub> Bn
<b>15</b>	H	H	4-CF <sub>3</sub> -Ph	4-CF <sub>3</sub> Bn
<b>16</b>	H	H	3-CF <sub>3</sub> -Ph	3-CH <sub>3</sub> OBn
<b>17</b>	H	H	3-CF <sub>3</sub> -Ph	3-CF <sub>3</sub> OBn
<b>18</b>	H	H	3-CF <sub>3</sub> -Ph	Et
<b>19</b>	H	H	3-CF <sub>3</sub> -Ph	4-CF <sub>3</sub> Bn
<b>20</b>	H	H	3-CF <sub>3</sub> -Ph	3-BnOBn
<b>21</b>	H	H	3-CF <sub>3</sub> -Ph	Bn
<b>22</b>	H	H	3-CF <sub>3</sub> -Ph	2,5-DiClBn
<b>23</b>	H	H	3-CF <sub>3</sub> -Ph	4- <i>t</i> -BuBn
<b>24</b>	Cl	H	3-CF <sub>3</sub> -Ph	3-CF <sub>3</sub> Bn
<b>25</b>	OBn	H	3-CF <sub>3</sub> -Ph	3-CF <sub>3</sub> Bn
<b>26</b>	OH	H	3-CF <sub>3</sub> -Ph	3-CF <sub>3</sub> Bn

**Table S2.** The chemical structures of PPAR $\gamma$  antagonists taken from Asteian's paper [2].



Compound	R	R <sub>1</sub>	R <sub>2</sub>	Compound	R	R <sub>1</sub>	R <sub>2</sub>
<b>27</b>	2-CH <sub>3</sub>	COOH	H	<b>SR1664</b>	4-NO <sub>2</sub>	COOH	CH <sub>3</sub>
<b>28</b>	2-NH <sub>2</sub>	COOH	H	<b>36</b>	3-iPr		CH <sub>3</sub>
<b>29</b>	2-NO <sub>2</sub>	COOH	H	<b>37</b>	3-iPr		CH <sub>3</sub>
<b>30</b>	3-iPr	COOH	CH <sub>3</sub>	<b>38</b>	3-iPr		CH <sub>3</sub>
<b>31</b>	3-	COOH	CH <sub>3</sub>	<b>39</b>	3-iPr	CONHOH	CH <sub>3</sub>
<b>32</b>	3-tBu	COOH	CH <sub>3</sub>	<b>40</b>	3-iPr	CONH <sub>2</sub>	CH <sub>3</sub>
<b>33</b>	4-iPr	COOH	CH <sub>3</sub>	<b>41</b>	3-iPr	CON(CH <sub>3</sub> ) <sub>2</sub>	CH <sub>3</sub>
<b>34</b>	4-tBu	COOH	CH <sub>3</sub>	<b>42</b>	3-iPr	COOH	CF <sub>3</sub>
<b>35</b>	3-	COOH	CH <sub>3</sub>	<b>43</b>	3-iPr	COOH	3-iPr





**Figure S1.** The chemical structures of PPAR $\gamma$  agonists.

**Table S3.** Glide docking scores (GScore, kcal/mol) of drug-like molecules extracted from a NCI database Against the PPAR $\gamma$  (2HFP) at allosteric site.

NCI ID	GScore	NCI ID	GScore	NCI ID	GScore	NCI ID	GScore	NCI ID	GScore
116	-6.57	47742	-8.92	95895	-5.44	130813	-8.28	171538	-6.30
153	-6.13	48151	-7.65	99547	-8.54	130842	-5.41	172540	-7.21
3098	-3.65	49628	-6.92	101523	-8.59	131366	-8.68	172846	-7.50
6918	-5.84	51478	-5.27	101672	-6.10	131367	-8.92	177363	-7.99
7579	-7.68	52003	-6.80	101793	-8.08	132263	-7.31	178023	-7.99
8008	-7.78	53199	-5.51	103843	-7.19	132898	-7.22	178889	-6.78
8490	-5.87	54906	-6.76	105274	-2.80	134118	-6.13	180617	-7.27
8609	-8.76	56243	-8.84	105337	-6.56	135634	-6.89	180627	-7.71
8611	-9.12	57034	-10.75	106156	-9.66	135848	-9.42	180642	-6.90
9011	-4.64	60616	-7.64	106221	-6.73	139461	-7.25	180648	-7.63
9349	-7.28	62571	-5.89	110347	-8.63	141337	-5.53	180661	-7.17
10406	-6.33	63837	-7.31	110559	-3.91	142333	-7.60	190528	-6.80
10671	-9.92	66072	-4.71	111593	-5.81	143351	-7.88	190748	-6.50
12985	-7.19	69584	-9.17	112828	-7.57	143748	-8.31	201618	-7.27
13481	-8.36	70824	-6.88	113311	-6.99	144441	-6.86	201666	-7.58
13843	-8.52	70914	-10.38	113915	-6.69	146005	-5.81	202677	-7.88
14013	-9.08	70972	-6.44	114133	-6.67	147980	-6.70	204583	-6.64
15285	-8.80	71012	-5.49	114631	-8.18	148001	-6.77	204590	-6.52
15903	-6.04	71682	-7.25	114673	-6.33	149543	-5.98	205546	-7.69
16764	-8.15	71790	-6.86	114819	-7.01	150206	-5.53	205684	-8.44
16765	-8.15	72559	-8.90	117195	-6.40	150386	-8.82	205811	-9.58
16768	-9.63	74975	-5.98	117777	-4.40	151215	-7.83	210344	-9.86
19223	-6.33	77700	-4.04	119707	-7.51	152426	-8.00	211226	-8.04
21312	-7.07	77720	-6.21	119765	-6.67	155243	-8.07	211831	-7.32
24914	-6.17	79023	-9.82	120183	-8.89	156601	-9.99	212018	-8.10
26870	-8.66	79566	-5.62	122309	-6.98	156773	-7.17	212032	-9.16
27265	-7.41	81129	-5.22	122514	-6.38	157402	-4.63	212112	-5.07
30019	-8.80	84538	-7.53	123112	-7.94	157967	-6.14	213899	-7.67
30967	-8.94	85154	-6.82	123222	-6.57	161387	-7.11	215556	-9.97
31546	-6.82	85267	-7.91	123247	-5.06	162183	-6.11	216451	-7.77
33408	-6.04	85410	-6.26	123976	-8.04	162501	-9.45	216506	-6.50
34567	-7.56	85518	-7.29	124442	-8.51	162765	-6.29	216694	-7.70
36487	-6.69	85679	-7.80	125281	-7.81	163369	-4.53	217080	-7.22
36506	-10.26	85740	-5.44	125661	-5.16	164089	-10.94	226116	-7.55
37117	-7.73	86711	-8.34	126424	-5.30	164113	-5.63	226178	-8.16
37815	-8.77	88972	-5.92	127678	-8.73	164377	-7.48	226517	-9.62
39006	-6.08	89808	-8.49	127690	-6.39	164929	-6.86	227395	-4.90
39612	-8.07	91332	-10.58	128094	-4.94	165995	-5.63	230297	-11.56
42399	-3.86	91397	-8.77	128583	-6.90	167739	-6.07	231315	-9.15
44491	-8.35	92204	-7.31	128594	-9.96	167819	-7.97	231923	-6.49
45093	-5.71	92228	-6.56	130101	-8.92	170757	-7.31	232022	-7.76
234698	-9.18	341661	-10.03	515421	-6.74	630981	-4.02	667386	-6.67
240360	-7.78	343544	-8.27	523235	-6.63	632016	-7.68	667708	-8.21
244974	-8.87	344240	-9.77	527570	-5.76	632242	-7.23	671438	-7.18
254681	-9.24	345725	-6.28	529321	-8.55	633057	-8.81	672084	-9.87
269193	-5.06	346878	-7.48	602681	-7.58	633971	-6.54	672293	-6.93
270150	-7.33	349963	-8.74	603656	-6.02	637660	-5.35	674002	-6.56
270734	-7.73	350111	-7.52	608550	-6.07	638038	-8.44	674012	-7.49
273905	-9.93	350986	-6.01	609357	-6.18	639829	-7.75	674612	-6.47

<b>277480</b>	-6.71	<b>353485</b>	-7.82	<b>609523</b>	-7.09	<b>640341</b>	-8.46	<b>675766</b>	-7.19
<b>279829</b>	-8.74	<b>356465</b>	-8.40	<b>610540</b>	-6.14	<b>640991</b>	-7.84	<b>675767</b>	-7.98
<b>281299</b>	-6.16	<b>356785</b>	-6.84	<b>612475</b>	-11.78	<b>640996</b>	-8.47	<b>676464</b>	-6.49
<b>284669</b>	-6.31	<b>357681</b>	-7.99	<b>612977</b>	-6.44	<b>641217</b>	-7.11	<b>676607</b>	-10.51
<b>289626</b>	-8.76	<b>359827</b>	-7.77	<b>613586</b>	-9.79	<b>641250</b>	-9.53	<b>677157</b>	-8.56
<b>291629</b>	-7.83	<b>363784</b>	-8.54	<b>613748</b>	-9.15	<b>641602</b>	-8.05	<b>679497</b>	-8.87
<b>292943</b>	-8.22	<b>363918</b>	-7.99	<b>617013</b>	-7.05	<b>642075</b>	-9.13	<b>679513</b>	-7.98
<b>294866</b>	-6.30	<b>364069</b>	-5.18	<b>618178</b>	-9.15	<b>642305</b>	-9.36	<b>680329</b>	-6.28
<b>296242</b>	-7.28	<b>364385</b>	-6.65	<b>618443</b>	-8.03	<b>642324</b>	-9.54	<b>681170</b>	-7.55
<b>298141</b>	-6.91	<b>365357</b>	-9.29	<b>618449</b>	-7.27	<b>643509</b>	-8.32	<b>681536</b>	-6.23
<b>299208</b>	-6.69	<b>366098</b>	-10.03	<b>618555</b>	-7.66	<b>644965</b>	-8.06	<b>681633</b>	-9.27
<b>299236</b>	-6.60	<b>367933</b>	-9.70	<b>618660</b>	-6.12	<b>645168</b>	-7.72	<b>681958</b>	-8.38
<b>300910</b>	-5.19	<b>368279</b>	-9.58	<b>618682</b>	-7.14	<b>645980</b>	-7.98	<b>682500</b>	-5.65
<b>304891</b>	-8.56	<b>371012</b>	-7.01	<b>618688</b>	-7.39	<b>646474</b>	-8.47	<b>682506</b>	-9.00
<b>308001</b>	-12.89	<b>371194</b>	-9.22	<b>619196</b>	-8.95	<b>647592</b>	-7.47	<b>683237</b>	-6.63
<b>309842</b>	-6.26	<b>371488</b>	-6.25	<b>620478</b>	-5.46	<b>648635</b>	-7.81	<b>683711</b>	-5.60
<b>310324</b>	-7.03	<b>372059</b>	-6.86	<b>622586</b>	-6.06	<b>648639</b>	-6.49	<b>685509</b>	-8.20
<b>310361</b>	-6.11	<b>372302</b>	-8.31	<b>622958</b>	-7.87	<b>648650</b>	-8.51	<b>685706</b>	-7.53
<b>310835</b>	-6.76	<b>372523</b>	-6.23	<b>623091</b>	-7.44	<b>648689</b>	-4.84	<b>687105</b>	-5.60
<b>313957</b>	-7.85	<b>372642</b>	-7.95	<b>623712</b>	-6.35	<b>651331</b>	-2.48	<b>687524</b>	-7.88
<b>317877</b>	-6.57	<b>374682</b>	-6.69	<b>623768</b>	-8.57	<b>652035</b>	-6.80	<b>687739</b>	-7.86
<b>318822</b>	-6.85	<b>375722</b>	-8.47	<b>624333</b>	-6.88	<b>652861</b>	-8.23	<b>687869</b>	-8.80
<b>319112</b>	-6.44	<b>379100</b>	-11.92	<b>624425</b>	-8.16	<b>652900</b>	-7.40	<b>688818</b>	-9.21
<b>319688</b>	-6.66	<b>379472</b>	-6.59	<b>624454</b>	-8.06	<b>654387</b>	-5.83	<b>690564</b>	-8.85
<b>320204</b>	-6.91	<b>380509</b>	-6.54	<b>624546</b>	-7.25	<b>655041</b>	-5.69	<b>691348</b>	-7.57
<b>320212</b>	-7.15	<b>381584</b>	-7.28	<b>624547</b>	-7.74	<b>656455</b>	-7.52	<b>691350</b>	-7.51
<b>320562</b>	-7.93	<b>400063</b>	-6.50	<b>624548</b>	-6.76	<b>657990</b>	-7.19	<b>691424</b>	-8.98
<b>320864</b>	-7.16	<b>401688</b>	-7.98	<b>627785</b>	-5.81	<b>658262</b>	-11.55	<b>691578</b>	-6.86
<b>325304</b>	-10.66	<b>401696</b>	-9.32	<b>627889</b>	-7.93	<b>658994</b>	-9.12	<b>693055</b>	-5.53
<b>328102</b>	-7.03	<b>401828</b>	-6.81	<b>629819</b>	-11.91	<b>659343</b>	-8.01	<b>693123</b>	-6.76
<b>331921</b>	-7.88	<b>403031</b>	-4.68	<b>629827</b>	-6.15	<b>661081</b>	-7.54	<b>694919</b>	-6.36
<b>333346</b>	-5.14	<b>405904</b>	-8.03	<b>630312</b>	-6.25	<b>662564</b>	-5.93	<b>695857</b>	-6.62
<b>335415</b>	-7.73	<b>406369</b>	-6.67	<b>630321</b>	-7.18	<b>664889</b>	-6.47	<b>731365</b>	-7.04
<b>335994</b>	-10.45	<b>408562</b>	-9.79	<b>630373</b>	-9.79	<b>665312</b>	-7.94	<b>338620</b>	-7.10
<b>337738</b>	-8.06	<b>409253</b>	-6.93	<b>512601</b>	-5.48	<b>666613</b>	-7.16		
<b>338540</b>	-8.51	<b>409615</b>	-7.79	<b>514213</b>	-6.78	<b>666714</b>	-7.03		

**Table S4.** Interacting residues of PPAR $\gamma$  antagonists at the orthosteric site.

<b>Compound</b>	<b>Interacting Residues</b>	<b>Compound</b>	<b>Interacting Residues</b>
<b>NSI</b>	Phe282, Phe363, Lys367, His449	<b>22</b>	Phe282, Phe363, Lys367
<b>SR1664</b>	Lys265, Ser289, Ser342, Lys367	<b>23</b>	Phe363
<b>SR11023</b>	Lys265, Ser289, Ser342	<b>24</b>	Phe282, Lys367, His449
<b>1</b>	Phe282, Phe363, Lys367, His449	<b>25</b>	Phe363
<b>2</b>	Phe282, His449	<b>26</b>	Phe282, Lys367
<b>3</b>	Phe282, Phe363, His449	<b>27</b>	Lys265, Ser289, Ser342
<b>4</b>	Lys367, His449	<b>28</b>	Lys265, Ser342
<b>5</b>	Lys367	<b>29</b>	Lys265, Ser289, Ser342
<b>6</b>	His449	<b>30</b>	Lys265, Ser289, Ser342
<b>7</b>	Phe282, Lys367, His449	<b>31</b>	Lys265, Phe282, Ser342
<b>8</b>	Phe282, Lys367, His449	<b>32</b>	Lys265, Phe282, Ser342
<b>9</b>	Phe282, His449	<b>33</b>	Lys265
<b>10</b>	Phe363, Lys367, His449	<b>34</b>	Lys265, Phe282, Ser289, Ser342
<b>11</b>	Phe282, Lys367	<b>35</b>	Lys265, Ser342, Tyr473
<b>12</b>	Lys367	<b>36</b>	Lys265, Ser342
<b>13</b>	Lys367, His449	<b>37</b>	Lys265, Phe282
<b>14</b>	Phe282, Lys367, His449	<b>38</b>	Lys265
<b>15</b>	Phe282, Lys367, His449	<b>39</b>	Lys265, Ser342
<b>16</b>	Phe282, Phe363, Lys367	<b>40</b>	Lys265, Glu291
<b>17</b>	Phe282, Lys367	<b>41</b>	Lys265, Gly284, Tyr327
<b>18</b>	Phe282, Lys367	<b>42</b>	Lys265
<b>19</b>	Phe282, Lys367	<b>43</b>	Lys265
<b>20</b>	NA	<b>44</b>	NA
<b>21</b>	Phe282, Phe363, Lys367		

**Table S5.** Interacting residues of PPAR $\gamma$  agonists at the orthosteric site and the allosteric site based on the Induced-Fit Docking.

Title	Ortho	Allo
<b>Rosiglitazone</b>	Ser289, His323, Gln286, Lys367	His323, Tyr327, Tyr473
<b>Lobeglitazone</b>	Ser289, His323, Gln286, Lys367	Lys265, Tyr473, Tyr327
<b>Pioglitazone</b>	Ser289, His323, Gln286, Lys367	His323, Tyr327, Tyr473, Leu340
<b>GW1929</b>	Leu340, Glu343, Lys265	HIE266, LYS265, Ser342
<b>Farglitazar</b>	Ser342	HIE266, LYS265, Ser342
<b>Edaglitazone</b>	Ser342	His323, Tyr327, Tyr473
<b>Amorfrutin 1</b>	Ser342, Glu343, Arg288	Glu343, Lys265
<b>Amorfrutin 2</b>	Ser342, Glu343, Arg288	Ser342
<b>MRL20</b>	Ser342	Ser342

## References

1. Hopkins, C.R.; O'Neil, S.V.; Laifersweiler, M.C.; Wang, Y.; Pokross, M.; Mekel, M.; Evdokimov, A.; Walter, R.; Kontoyianni, M.; Petrey, M.E.; et al. Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR- $\gamma$  binding agents with potential application to the treatment of osteoporosis. *Bioorganic Med. Chem. Lett.* **2006**, *16*, 5659–5663. <https://doi.org/10.1016/j.bmcl.2006.08.003>.
2. Asteian, A.; Blayo, A.-L.; He, Y.; Koenig, M.; Shin, Y.; Kuruvilla, D.S.; Corzo, C.A.; Cameron, M.D.; Lin, L.; Ruiz, C.; et al. Design, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPAR $\gamma$  Antagonists. *ACS Med. Chem. Lett.* **2015**, *6*, 998–1003. <https://doi.org/10.1021/acsmedchemlett.5b00218>.